COMP <GO>
MDGL vs SYRE // OPERATING MARGIN
Madrigal Pharmaceuticals Inc. (NASDAQ) VS. Spyre Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: MDGL 3
— SYRE 6
■ METRIC PARITY
LAST: $431.70 (+0.16%) • MKT CAP: $9.97B
operating-margins
-31.30%
LAST: $98.96 (-0.79%) • MKT CAP: $10.33B
operating-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDGL VS. SYRE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDGL | SYRE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -29.70% | -20.00% | -9.70 | SYRE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.91% | -1.64% | -0.27 | SYRE | /fcf-yield <GO> |
| Operating Margin ACTIVE | -31.30% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -30.10% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 17.60% | +162.40 | MDGL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.65 | 26.00 | -18.35 | SYRE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 5/9 | +1.00 | MDGL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.6 | 61.9 | -31.30 | SYRE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.89 | +0.19 | MDGL | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 22.0x | +2.00 | SYRE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.97B | $10.33B | -$358.9M | SYRE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDGL REV | SYRE REV | MDGL GROSS % | SYRE GROSS % | MDGL FCF | SYRE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $958.4M | $0 | — | — | -$190.0M | -$169.3M |
| FY 2024 | $180.1M | $0 | 96.5% | — | -$457.0M | -$157.4M |
| FY 2023 | $0 | $886.0K | — | — | -$324.2M | -$99.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDGL // BETA 1.08
SYRE // BETA 0.89